Pfizer’s current dividend yield of approximately 6.8% stands well above the industry average of 3% to 4%, driven largely by the post-pandemic decline in COVID-19 vaccine and antiviral revenues. Annual top-line figures have slipped roughly 40% from the 2022 peak of just over $100 billion, prompting a market re-rating that may overstate downside risk. Despite this, Pfizer has delivered 16 consecutive years of dividend increases, reflecting confidence in cash flow generation. The 2023 acquisition of Seagen strengthens its oncology portfolio, and management targets at least eight new blockbuster drugs—each exceeding $1 billion in annual sales—by 2030. These candidates, together with late-stage assets in inflammation, rare disease and immunology, underpin projected new revenue of $20 billion to $25 billion over the next five years, supporting continued dividend growth even as R&D outcomes remain subject to clinical and regulatory variability.

Pfizer will host a live webcast featuring CEO Albert Bourla on January 12, 2026 at 9:45 a.m. PST during the 44th Annual J.P. Morgan Healthcare Conference. Investors and the general public can register and access the presentation via www.pfizer.com/investors, where a replay and transcript will be posted within 24 hours and remain available for at least 90 days. Topics expected to be covered include updates on pipeline progress, financial guidance, capital allocation priorities—encompassing dividends and share repurchases—and strategic objectives following the Seagen acquisition. The webcast materials will also address Pfizer’s long-term R&D strategy, manufacturing capacity expansion, and collaboration efforts to enhance global access to innovative therapies.